Adamax
peptide · headlineResearch use onlyUpregulates BDNF (brain-derived neurotrophic factor) expression in hippocampus and cortex
Overview
Adamax is a next-generation nootropic peptide and enhanced Semax analog featuring N-terminal acetylation and C-terminal adamantane modification for superior stability and blood-brain barrier penetration. It upregulates BDNF, enhances TrkB receptor sensitivity, modulates monoamines, and provides neuroprotection against oxidative stress and excitotoxicity.
How it works
- Upregulates BDNF (brain-derived neurotrophic factor) expression in hippocampus and cortex
- Enhances TrkB receptor sensitivity for improved neurotrophin signaling
- Modulates monoamine neurotransmitter levels (dopamine, norepinephrine, serotonin)
- Activates neuroprotective pathways reducing oxidative stress
- Stabilizes microtubules through ADNP-derived mechanisms
- Reduces excitotoxicity through neuromodulation
Dosing
Standard dose: 300-1000 mcg daily via intranasal spray or injection, administered daily with gradual titration.
Caution: Start with the lowest recommended dose (300 mcg) to assess individual tolerance. Adamax can cause insomnia and anxiety in sensitive individuals; avoid dosing after 2 PM. Do not exceed 1000 mcg daily without medical supervision. Limited long-term human safety data exists.
Cycling
- Can be used daily without cycling; however, some users rotate 5 days on / 2 days off to prevent tolerance development. Nasal mucosa health should be monitored during extended use.
- Daily administration recommended without cycling for cognitive support. Some protocols suggest 3 weeks on / 1 week off for tolerance management.
Side effects
- Common
- Nasal irritation or congestion (intranasal administration)
- Mild headache (usually transient)
- Slight insomnia if dosed late in the day
- Warnings
- May cause anxiety or overstimulation at high doses
- Risk of sleep disruption if taken in evening
- Limited long-term human safety data available
- Long Term
- Long-term safety profile unknown in humans
- Extrapolated from Semax clinical experience only
Stacking & combinations
- With
Semax
- Benefit
Additive BDNF and neuroprotective effects; Adamax potentially superior bioavailability
- With
P21
- Benefit
Combined cognitive enhancement and neuroprotection; complementary mechanisms of action
- With
BPC-157
- Benefit
Synergistic neuroprotection and tissue repair; enhanced recovery from neurological stress
Lifestyle support
- Diet
Nutrient-dense diet rich in antioxidants. Adequate hydration.
- Sleep
Adequate sleep (7–9 hours). Stable circadian rhythm. Stress management supports neuroprotective benefits.
- Timing
Avoid late-day dosing to prevent sleep disruption.
- Exercise
Regular aerobic exercise.
Reconstitution calculator
Subcutaneous Injection= 0.06 mL on a U-100 insulin syringe
Assumes a U-100 insulin syringe (100 units = 1 mL). This is a preparation aid, not a protocol — dose and route are the prescriber's decision. Refrigerate at 2-8°C (35.6-46.4°F) after reconstitution with bacteriostatic water. Use within 2-4 weeks. Discard if solution becomes discolored.
Chemistry & PK
- Sequence
- Ac-SEMAX-Adamantyl
- Half Life
- 2-4 hours (intranasal); 6-8 hours (subcutaneous)
- Degradation
- Enzymatic degradation by serum proteases; slower degradation than native Semax due to adamantane modification.
- Molecular Weight
- 1568
- Molecular Formula
- C72H111N21O13
- Tissue Specificity
- CNS-specific distribution with high hippocampal, cortical, and striatal accumulation.
Bioavailability
- Oral
- Not available orally - peptide degradation in GI tract prevents absorption.
- Subq
- High bioavailability via subcutaneous injection, bypasses first-pass metabolism and blood-brain barrier restrictions via receptor-mediated transport.
Storage & handling
- Lyophilized
Store at -20°C (-4°F) in a cool, dark place away from light and moisture. Stability of 2+ years when properly stored.
- Reconstituted
Refrigerate at 2-8°C (35.6-46.4°F) after reconstitution with bacteriostatic water. Use within 2-4 weeks. Discard if solution becomes discolored.
Used for
No condition evidence rows yet.
Legal / compounding
- EU
- Not Approved - Research Chemical
- FDA
- Not Approved - Research Chemical
- Canada
- Not Approved - Research Chemical
- Australia
- Not Approved - Research Chemical
Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.